Low levels of intraplatelet cGMP in IDDM.
OBJECTIVE
To determine the levels of intraplatelet cGMP, an index of activity of the antiaggregatory nitric oxide pathway, in IDDM patients.


METHODS
We measured intraplatelet and plasmatic cGMP levels in 22 IDDM patients and 22 age- and sex-matched control subjects.


RESULTS
Intraplatelet cGMP levels decreased in the IDDM patients (0.32 +/- 0.16 pmol/10(9) platelets) when compared with the control group (0.52 +/- 0.32 pmol/10(9) platelets), P = 0.032. Plasmatic cGMP levels were not significantly different between groups. Intraplatelet cGMP levels correlated negatively with the duration of the disease (r = -0.43, P < 0.05).


CONCLUSIONS
IDDM patients have lower levels of intraplatelet cGMP, which may be responsible in part for their platelet hyperactivity.
Amado
J A
JA
Department of Medicine, Hospital Universitario Marques de Valdecilla, University of Cantabria, Spain.
Salas
E
E
Botana
M A
MA
Poveda
J J
JJ
Berrazueta
J R
JR
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D001792:Blood Platelets / Q000737:chemistry*; D006152:Cyclic GMP / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D012016:Reference Values
D001786:Blood Glucose; D006152:Cyclic GMP; D006442:Glycated Hemoglobin